Viridian Therapeutics
VRDN
11 hedge funds and large institutions have $581K invested in Viridian Therapeutics in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
10% more funds holding
Funds holding: 10 → 11 (+1)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
26% less capital invested
Capital invested by funds: $781K → $581K (-$200K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$24.1K |
| 2 |
Nomura Holdings
Tokyo,
Japan
|
+$13.9K |
| 3 |
ICAS
Investors Capital Advisory Services
Lynnfield,
Massachusetts
|
+$13.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$11.9K |
| 5 |
TDC
Thompson Davis & Co
Richmond,
Virginia
|
+$9.05K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$58K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$48.9K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$17K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$11.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$578 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
HighTower Advisors
Chicago,
Illinois
| $256K | – | – | – |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $130K | – | – | – |
|
|
PCM
3
Perkins Capital Management
Wayzata,
Minnesota
| $77K | -$48.9K | -254 | -36% |
|
|
ICAS
4
Investors Capital Advisory Services
Lynnfield,
Massachusetts
| $28K | +$13.7K | +71 | +72% |
|
|
VKH
5
Virtu KCG Holdings
New York
| $24K | -$11.2K | -58 | -29% |
|
|
6
Citadel Advisors
Miami,
Florida
| $21K | +$24.1K | +125 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $15K | +$11.9K | +62 | +221% |
|
|
8
Nomura Holdings
Tokyo,
Japan
| $12K | +$13.9K | +72 | New |
|
9
Creative Planning
Overland Park,
Kansas
| $10K | – | – | – |
|
|
TDC
10
Thompson Davis & Co
Richmond,
Virginia
| $8K | +$9.05K | +47 | New |
|
|
11
Bank of America
Charlotte,
North Carolina
| – | -$58K | -277 | Closed |
|
|
TSS
12
Two Sigma Securities
New York
| – | -$17K | -80 | Closed |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| – | -$578 | -3 | Closed |
|
14
Citigroup
New York
| – | +$385 | +2 | New |
|
VRDN Hedge Fund Activity: Q4 2015 in Review
11 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q4 2015, worth a combined $581K — down 26% from $781K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new VRDN positions and 3 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $24.1K. The largest seller was Bank of America, exiting entirely with an estimated $58K sold.
- 11 institutional investors held Viridian Therapeutics (VRDN) as of Q4 2015, up from 10 in Q3 2015.
- Funds reported $581K of Viridian Therapeutics stock for Q4 2015, down 26% quarter-over-quarter.
- 4 funds opened new Viridian Therapeutics positions in Q4 2015 and 3 closed out, a net change of +1 holder.
- The largest Viridian Therapeutics buyer in Q4 2015 was Citadel Advisors, an estimated $24.1K added.
- The largest Viridian Therapeutics seller in Q4 2015 was Bank of America, an estimated $58K sold.
Based on aggregated 13F filings for Q4 2015.